Vesica Health, Inc.

Vesica Health Overview

Vesica Health, Inc., based in Irvine, California, is transforming the early detection of bladder cancer with a clear mission to improve patient outcomes through precision, noninvasive testing. The flagship product, AssureMDx, is a clinically validated, urine-based liquid biopsy test designed to optimize the triage of hematuria patients and enhance early bladder cancer detection. With 96% sensitivity and 99% negative predictive value (NPV), AssureMDx offers unparalleled accuracy, empowering clinicians to make more confident decisions while reducing unnecessary procedures and associated healthcare costs.

Value Proposition

Vesica Health represents a unique investment opportunity in the rapidly growing precision oncology market. By addressing critical unmet needs in bladder cancer care, the company aims to transform diagnostic pathways, streamline patient management, and improve survival rates. Vesica Health leverages cutting-edge multi-omics technology and proprietary biomarkers, validated through 22 peer-reviewed studies involving over 6,000 patients, providing a robust foundation for clinical and commercial success.

Historical Achievements

2024 marked a transformative year for Vesica Health. The company successfully launched AssureMDx, established laboratory operations at a state-of-the-art facility in Irvine, and achieved prestigious CAP Accreditation alongside CLIA and California State licensing. Additionally, Vesica Health initiated key research collaborations to advance its R&D pipeline, focusing on next-generation diagnostic solutions.

Clinical Opportunity

Bladder cancer is one of the most prevalent and costly cancers globally. Hematuria management and early detection represent a $6B market, driven by approximately 17 million Americans presenting with hematuria annually, yet only 12% are referred to a urologist, leading to 20,000 missed or delayed diagnoses and increased mortality. Standard diagnostics—cytology, cystoscopy, and CT scans—are limited by low sensitivity, invasiveness, and radiation risks. These challenges highlight the urgent need for non-invasive tools to improve risk stratification, enable earlier detection, and reduce invasive procedures.

Management Team

Vesica Health is led by a seasoned management team with decades of experience in diagnostics, commercialization, and precision oncology. The leadership team combines scientific expertise, operational excellence, and strategic vision to execute on Vesica Health’s ambitious growth plans.

Looking Ahead

With a strong operational foundation, regulatory approvals, and market-ready solutions, Vesica Health is poised to scale AssureMDx’s adoption, expand into international markets, and advance next-generation products in bladder cancer care. This moment represents a compelling opportunity to invest in Vesica Health and support its mission to redefine bladder cancer diagnostics while delivering significant value to stakeholders.

For additional information or partnership inquiries, please contact public.relations@vesicahealth.com.